Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment

Inclusion Criteria: * Patients aged 60 years or older * With newly diagnosed acute myeloid leukemia (AML) (short course treatment with hydroxyurea and or steroids is acceptable). Patients with AML secondary to an antecedent Myelodysplastic Syndromes (MDS) or Myeloproliferative Neoplasms (MPN) are eligible, as those with therapy-related AML. * Eligible for intensive chemotherapy in the investigator's opinion * Leukaemia-associated immunophenotypes (LAIP) detected at screening allowing flow cytometry (FCM)-based Minimal Residual Disease monitoring (Phase II only). * Eastern Cooperative Oncology Group (ECOG) performance status ≤2 * Aspartate transaminase (AST) and Alanine transaminanse (ALT) ≤ 3.0 times upper the limit of normal (ULN) and total and direct serum bilirubin ≤ 1.5 x ULN unless considered due to leukemia Estimated glomerular filtration rate (GFR) ≥ 50 mL/min according to the MDRD equation * Written informed consent obtained prior to any screening procedures * Eligible for National Health Insurance in France Exclusion Criteria: * Myeloid Sarcoma with \< 20% bone marrow blasts * Patient who has received a vaccine injection with live-attenuated virus in the last three weeks * Proven central nervous system leukemic involvement * Favorable risk cytogenetics: t(15;17), t(8;21), inv(16) or t(16;16) or presence of PML-RARA, RUNX1-RUNX1T1 or CBFB-MYH11 fusion transcript. * Presence of FLT3-ITD or TKD mandating treatment with midostaurin. * Concurrent therapy with any cytot…